Portal hypertension and liver cirrhosis in rats: Effect of the β3-adrenoceptor agonist SR58611A

British Journal of Pharmacology

Volumn 167, Issue 5, 2012, Pages 1137-1147

  Vasina, Valentina ^a   Giannone, Ferdinando ^a,b   Domenicali, Marco ^a,b   Latorre, Rocco ^a   Berzigotti, Annalisa ^a   Caraceni, Paolo ^a,b   Zoli, Marco ^a   De Ponti, Fabrizio ^a   Bernardi, Mauro ^a,b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

3 adrenoceptor; cirrhosis; portal hypertension; systemic haemodynamics

Indexed keywords

1 (2 ETHYLPHENOXY) 3 (1,2,3,4 TETRAHYDRO 1 NAPHTHYLAMINO) 2 PROPANOL OXALATE; AMIBEGRON; BETA 3 ADRENERGIC RECEPTOR; CARBON TETRACHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE REGULATION; CENTRAL VENOUS PRESSURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG INFUSION; HEART; HEART INDEX; HEMODYNAMICS; IMMUNOHISTOCHEMISTRY; LIVER; LIVER CIRRHOSIS; MALE; MEAN ARTERIAL PRESSURE; MESENTERIC ARTERY; MOLECULAR BIOLOGY; NONHUMAN; PORTAL HYPERTENSION; PORTAL VEIN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RAT; SYSTEMIC CIRCULATION; TISSUE SECTION; VASCULAR RESISTANCE; VEIN DILATATION;

ADRENERGIC BETA-3 RECEPTOR ANTAGONISTS; ANIMALS; BLOOD PRESSURE; HEMODYNAMICS; HYPERTENSION, PORTAL; LIVER; LIVER CIRRHOSIS; MALE; MYOCARDIUM; PORTAL VEIN; RATS; RATS, WISTAR; RECEPTORS, ADRENERGIC, BETA-3; TETRAHYDRONAPHTHALENES; VASODILATION;

EID: 84867290755     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2012.02074.x     Document Type: Article

References (32)

1. Albillos A, de la Hera A, González M, Moya JL, Calleja JL, Monserrat J, et al,. (2003). Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement. Hepatology 37: 208-217. (Pubitemid 36042162)
2. Alexander SP, Mathie A, Peters JA, (2011). Guide to receptors and channels (GRAC), 5th edition. Br J Pharmacol 164 (Suppl 1): S1-324.
3. American Veterinary Medical Association (2007). AVMA guidelines on euthanasia. Available at: http://oacu.od.nih.gov/regs/AVMA-Euthanasia-2007.pdf (accessed 5 September 2012).
4. 3-adrenoceptor mRNA in human tissues. Eur J Pharmacol 289: 223-228.
5. Bianchetti A, Manara L, (1990). In vitro inhibition of intestinal motility by phenylethanolaminotetralines: evidence of atypical beta-adrenoceptors in rat colon. Br J Pharmacol 100: 831-839. (Pubitemid 20233327)
6. Bosch J, Berzigotti A, Garcia-Pagan JC, Abraldes JG, (2008). The management of portal hypertension: rational basis, available treatments and future options. J Hepatol 48 (Suppl 1): S68-S92.
7. Chan CC, Hwang SJ, Lee FY, Wang SS, Chang FY, Li CP, et al,. (1997). Prognostic value of plasma endotoxin levels in patients with cirrhosis. Scand J Gastroenterol 32: 942-946. (Pubitemid 27382041)
8. 3-adrenoceptors. Br J Pharmacol 114: 1447-1453.
9. 3-adrenoceptors in the human colon using the beta 3-selective adrenoceptor antagonist, SR 59230A. Br J Pharmacol 117: 1374-1376. (Pubitemid 26116760)
10. Domenicali M, Caraceni P, Giannone F, Pertosa AM, Principe A, Zambruni A, et al,. (2009). Cannabinoid type 1 receptor antagonism delays ascites formation in rats with cirrhosis. Gastroenterology 137: 341-349.
11. Donckier JE, Massart PE, Van Mechelen H, Heyndrickx GR, Gauthier C, Balligand JL, (2001). Cardiovascular effects of beta 3-adrenoceptor stimulation in perinephritic hypertension. Eur J Clin Invest 31: 681-689. (Pubitemid 32756616)
12. García-Pagán JC, Navasa M, Rivera F, Bosch J, Rodés J, (1992). Lymphocyte beta2-adrenoceptors and plasma catecholamines in patients with cirrhosis. Gastroenterology 102: 2015-2023.
13. Garcia-Tsao G, Sanyal AJ, Grace ND, Carey W,; Practice Guidelines Committee of the American Association for the Study of Liver Diseases, Practice Parameters Committee of the American College of Gastroenterology (2007). Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology 46: 922-938. (Pubitemid 47436138)
14. 3- adrenoceptors in the cardiovascular system. Trends Pharmacol Sci 21: 426-431.
15. Gerbes AL, Remien J, Jungst D, Sauerbruch T, Paumgartner G, (1986). Evidence for down-regulation of beta-2-adrenoceptors in cirrhotic patients with severe ascites. Lancet 1: 1409-1411.
16. Giudice A, Croci T, Bianchetti A, Manara L, (1989). Inhibition of rat colonic motility and cardiovascular effects of new gut-specific β-adrenergic phenylethanolaminotetralines. Life Sci 44: 1411-1417. (Pubitemid 19150100)
17. Jiménez W, Claria J, Arroyo V, Rodés J, (1992). Carbon tetrachloride induced cirrhosis in rats: a useful tool for investigating the pathogenesis of ascites in chronic liver disease. J Gastroenterol Hepatol 7: 90-97.
18. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). NC3Rs Reporting Guidelines Working Group. Br J Pharmacol 160: 1577-1579.
19. 1-adrenoceptors, relax the rat isolated mesenteric artery. Br J Pharmacol 140: 3-12. (Pubitemid 37175825)
20. McGrath J, Drummond G, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
21. 3-selective antagonists, aryloxypropanolaminotetralins. Br J Pharmacol 117: 435-442. (Pubitemid 26057651)
22. 3 adrenoceptors in the myocardium. Eur J Heart Fail 9: 1163-1171. (Pubitemid 350148276)
23. 3-adrenoceptor agonist, in the dog: lack of central effect. Fundam Clin Pharmacol 13: 180-186. (Pubitemid 32324245)
24. Pelat M, Verwaerde P, Galitzky J, Lafontan M, Berlan M, Senard JM, et al,. (2003). High isoproterenol doses are required to activate beta3-adrenoceptor-mediated functions in dogs. J Pharmacol Exp Ther 304: 246-253. (Pubitemid 36008935)
25. 3-adrenoceptors in the cardiovascular system: putative roles in human pathologies. Pharmacol Ther 111: 652-673. (Pubitemid 44137382)
26. Sanyal AJ, Bosch J, Blei A, Arroyo V, (2008). Portal hypertension and its complications. Gastroenterology 134: 1715-1728. (Pubitemid 351626956)
27. 3-adrenoceptors for intrahepatic resistance and portal hypertension in liver cirrhosis. Hepatology 50: 1924-1935.
28. Trochu JN, Leblais V, Rautureau Y, Bévérelli F, Le Marec H, Berdeaux A, et al,. (1999). Beta 3-adrenoceptor stimulation induces vasorelaxation mediated essentially by endothelium-derived nitric oxide in rat thoracic aorta. Br J Pharmacol 128: 69-76. (Pubitemid 29425269)
29. Turnes J, Hernández-Guerra M, Abraldes JG, Bellot P, Oliva R, García-Pagán JC, et al,. (2006). Influence of beta-2 adrenergic receptor gene polymorphism on the hemodynamic response to propranolol in patients with cirrhosis. Hepatology 43: 34-41. (Pubitemid 43733589)
30. 3-adrenoceptor as a therapeutic target: current perspectives. Pharmacol Res 59: 221-234.
31. Viard P, Macrez N, Coussin F, Morel JL, Mironneau J, (2000). Beta-3 adrenergic stimulation of L-type Ca(2+) channels in rat portal vein myocytes. Br J Pharmacol 129: 1497-1505. (Pubitemid 30175724)
32. 3- adrenoceptors. Naunyn Schmiedebergs Arch Pharmacol 374: 385-398.